Ovarian cancer in Portugal: a real-world evidence review

The primary objective of this study was to address the gap in national data on the ovarian cancer (OC) patient pathway in Portugal. We aggregated and synthesized real-world evidence (RWE) studies conducted by AstraZeneca Portugal between 2016 and 2025 on OC, including fallopian tube and primary peritoneal carcinoma, to provide an overview of the patient journey. Moreover, we performed a literature search to include additional studies, using the keywords “ovarian cancer” AND “real world” OR “RWE” OR “real world evidence” AND “patient journey” AND “Portugal,” but no relevant citations were identified in PubMed. This review includes five studies presented at various national and international meetings. The PADOC and the IPOP OC studies evaluated the prevalence of BRCA pathogenic variants in somatic and germline related to OC; the MAP-OCSur study focused on characterization of OC surgery in Portugal; the Portuguese subanalysis of the RESPONSE trial described the standard of care in patients with OC in Portugal; and the OLA effectiveness evaluated the use of olaparib in platinum-sensitive relapsed OC. The mentioned RWE studies play a crucial role in characterizing the OC patient pathway in Portugal, by enhancing the understanding of both the disease and patient profile, as well as identifying existing evidence gaps. This review illustrates the current state of OC care in Portugal, raising awareness of challenges and highlighting opportunities to improve access and patient outcomes.